Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:46 2024-04-29 EDT			5-day change	1st Jan Change
884.8 ^DKK	-0.20%		+1.09%	+26.74%

04-29	One dose of Novo Nordisk's Wegovy back in supply, FDA website shows	RE
04-29	Big tech saves the day, again

NOVO NORDISK : Jefferies reiterates its Sell rating

September 14, 2021 at 05:04 am

Peter Welford from Jefferies retains his negative opinion on the stock with a Sell rating. The target price is increased from DKK 415 to DKK 465.

Latest news about Novo Nordisk A/S

One dose of Novo Nordisk's Wegovy back in supply, FDA website shows	04-29	RE
Big tech saves the day, again	04-29
NOVO NORDISK : UBS sticks Neutral	04-29	ZD
NOVO NORDISK : JP Morgan gives a Buy rating	04-25	ZD
Scholz promises support for pharma sector in Germany as Merck invests	04-25	RE
Sector Update: Health Care Stocks Slipping Late Afternoon	04-24	MT
Sector Update: Health Care	04-24	MT
Novo Nordisk's Wegovy FDA Approval for Heart Health Opens Door to Medicare Access, KKF Says	04-24	MT
US Senate committee investigates pricing of Novo's Ozempic and Wegovy	04-24	RE
Novo Nordisk Probed by Senate Committee on Weight-Loss Drug Prices	04-24	DJ
NOVO NORDISK : Bernstein maintains a Buy rating	04-24	ZD
Germany's Evotec appoints Christian Wojczewski as CEO	04-23	RE
UK stocks may finally be back in fashion	04-23	RE
Health Care Climbs on Earnings Hopes -- Health Care Roundup	04-22	DJ
Eli Lilly to acquire manufacturing facility from Nexus Pharma	04-22	RE
India's Biocon developing its own version of Wegovy, clinical trial likely next year	04-18	RE
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm	04-15	RE
Biophytis: patent application filed in the field of obesity	04-15	CF
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup	04-12	DJ
European Equities Close Mixed in Friday Trading; German Inflation Slows, UK GDP Rises	04-12	MT
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	04-12	DJ
Sector Update: Health Care Stocks Steady Pre-Bell Friday	04-12	MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says	04-12	MT
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	04-12	MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says	04-12	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVO NORDISK : Novo’s bag is full of pearls!

March 15, 2024 at 05:22 am

Kasim Kutay, CEO of Novo Holdings: Catalent purchase marks new era of acquisitions

March 12, 2024 at 07:21 am

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

884.8 DKK

Average target price

904.2 DKK

Spread / Average Target

+2.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+26.74%	567B
ELI LILLY AND COMPANY	+26.47%	664B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.43%	234B
NOVARTIS AG	+4.71%	199B
ROCHE HOLDING AG	-9.53%	196B
AMGEN INC.	-4.04%	148B
PFIZER, INC.	-10.94%	145B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Jefferies reiterates its Sell rating

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals